Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4981391 | 0.82 | HSP90AB1 (0.51) | ALDH1A1KDM4EHSP90AB1HRH3KCNH2 | |
| SCHEMBL4978554 | 0.79 | HSP90AB1 (0.63) | HSP90AB1HRH3KCNH2L3MBTL3L3MBTL1 | |
| SCHEMBL4976442 | 0.78 | MAPT (0.49) | ALDH1A1MAPTNPSR1GAAHSP90AB1 | |
| SCHEMBL4978120 | 0.78 | HSP90AB1 (0.48) | HSP90AB1L3MBTL1 | |
| SCHEMBL4977057 | 0.78 | HSP90AB1 (0.48) | KDM4EHSP90AB1 | |
| SCHEMBL4980054 | 0.78 | HSP90AA1 (0.41) | MAPTHSP90AB1 | |
| SCHEMBL4979083 | 0.78 | ALDH1A1 (0.56) | ALDH1A1KDM4EHSP90AB1HRH3KCNH2 | |
| SCHEMBL4978931 | 0.77 | HSP90AB1 (0.45) | MAPTKDM4EHSP90AB1 | |
| SCHEMBL4980250 | 0.77 | KDM4E (0.58) | ALDH1A1MAPTKDM4EGAAHSP90AB1 | |
| SCHEMBL4980365 | 0.77 | HSP90AB1 (0.48) | ALDH1A1KDM4EHSP90AB1HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | HRH3, HRH4, HRH2 | ALDH1A1 1142/4885MAPT 2301/4885NPSR1 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.